Affordable Access

deepdyve-link
Publisher Website

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.

Authors
  • Deng, Lisi1
  • Li, Chunna1
  • Zeng, Qi2
  • Liu, Xi1
  • Li, Xinghua1
  • Zhang, Haitang1
  • Hong, Zhongsi3
  • Xia, Jinyu4
  • 1 Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China. , (China)
  • 2 Cancer Center, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China. , (China)
  • 3 Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China. Electronic address: [email protected] , (China)
  • 4 Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China. Electronic address: [email protected] , (China)
Type
Published Article
Journal
The Journal of infection
Publication Date
Jul 01, 2020
Volume
81
Issue
1
Identifiers
DOI: 10.1016/j.jinf.2020.03.002
PMID: 32171872
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Corona Virus Disease 2019 (COVID-19) due to the 2019 novel coronavirus (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China. We aimed to compare arbidol and lopinavir/ritonavir(LPV/r) treatment for patients with COVID-19 with LPV/r only. In this retrospective cohort study, we included adults (age≥18years) with laboratory-confirmed COVID-19 without Invasive ventilation, diagnosed between Jan 17, 2020, and Feb 13, 2020. Patients, diagnosed after Jan 17, 2020, were given oral arbidol and LPV/r in the combination group and oral LPV/r only in the monotherapy group for 5-21 days. The primary endpoint was a negative conversion rate of coronavirus from the date of COVID-19 diagnosis(day7, day14), and assessed whether the pneumonia was progressing or improving by chest CT (day7). We analyzed 16 patients who received oral arbidol and LPV/r in the combination group and 17 who oral LPV/r only in the monotherapy group, and both initiated after diagnosis. Baseline clinical, laboratory, and chest CT characteristics were similar between groups. The SARS-CoV-2 could not be detected for 12(75%) of 16 patients' nasopharyngeal specimens in the combination group after seven days, compared with 6 (35%) of 17 in the monotherapy group (p < 0·05). After 14 days, 15 (94%) of 16 and 9 (52·9%) of 17, respectively, SARS-CoV-2 could not be detected (p < 0·05). The chest CT scans were improving for 11(69%) of 16 patients in the combination group after seven days, compared with 5(29%) of 17 in the monotherapy group (p < 0·05). In patients with COVID-19, the apparent favorable clinical response with arbidol and LPV/r supports further LPV/r only. Copyright © 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Report this publication

Statistics

Seen <100 times